New

Global ETF Survey 2026 Available: How 620 Professionals Select ETFs. Access the Report →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

Access the report

›ETF Issuers›First Trust›FBT

FBT

First Trust NYSE Arca Biotechnology UCITS ETF

Passive ETF Equity

The FBT Exchange Traded Fund (ETF) is provided by First Trust. It is built to track an index: NYSE Arca Biotechnology Index. The FBT ETF provides physical exposure, so by buying it you actually own parts of all the 30 underlying holdings. The dividend policy is capitalization.

$33.96

-$0.15 (-0.44%) yesterday

8:00 AM 11/04/26 Closed

1D price range

$33.68$34.72

52W price range

$23.00$34.72

YTD Perf.

+33.88%

YTD Flows

Annualized volatility

Fund AuM

€17M

Share class AuM

€17M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

IE00BL0L0H60

TER

0.6%

Inception date

5/27/2020

Issuer

First Trust

Benchmark

NYSE Arca Biotechnology Index

Replication method

Dividend policy

Capitalization

Compare similar ETFs

ETF Name	1w perf.
FBT First Trust NYSE Arca Biotechnology Index Fund ETF	+0.85%
FBT First Trust NYSE Arca Biotechnology ETF	+0.56%
IBB iShares Biotechnology ETF	+1.59%
TMED T. Rowe Price Health Care ETF	-0.19%
PBE Invesco Dynamic Biotechnology & Genome ETF	+1.63%
IBBQ Invesco Nasdaq Biotechnology ETF	+1.61%
203780 Mirae Asset TIGER NASDAQ BIO ETF	+4.03%
BTEE iShares Nasdaq US Biotechnology UCITS ETF	+1.60%
CURE VanEck Genomics and Healthcare Innovators UCITS ETF	-0.72%
00678 CAPITAL NASDAQ BIOTECHNOLOGY INDEX ETF	+1.48%
2B78 iShares Healthcare Innovation UCITS ETF	+0.99%
HTEC Robo Global Healthcare Technology and Innovation ETF	+1.07%
WDNA WisdomTree BioRevolution UCITS ETF	-0.21%
LIV Smart Healthcare Innovation ETF	+2.76%
XGEN Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF	-0.88%

API

PerformanceDec 31, 2025 - Nov 3, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 09/30/26

Healthcare

99.88%

Unavailable

0.12%

Latest FBT news

BioTech & Genomics ETFs Shine Amid Sector Rotation

Moving Markets · July 30, 2024

FAQ about FBT

FBT is a passively managed ETF that invests in the US Health Care segment.

FBT tracks the NYSE Arca Biotechnology NTR Index - USD, through a full replication replication method.

FBT carries a total expense ratio (TER) of 0.6%.

FBT was introduced to the market on May 27, 2020.

First Trust NYSE Arca Biotechnology UCITS ETF, FBT, is provided by First Trust. Learn more about First Trust here.

FBT oversees €17M in assets as of November 3, 2026.

FBT follows a capitalizing, meaning it reinvests income within the fund.

As of September 30, 2026, FBT has significant geographic allocations in USA, Switzerland and Denmark.

As of September 30, 2026, FBT focuses largely on Healthcare.

As of September 30, 2026, FBT holds 30 positions in its portfolio, with 56.62% of assets concentrated in its top 15 holdings.

As of September 30, 2026, FBT top three holdings include Natera, Inc., Halozyme Therapeutics, Inc. and Illumina, Inc..

The base currency of FBT is USD.

Top 10 holdings

Data as of 09/30/26

Natera, Inc.

4.72%

Halozyme Therapeutics, Inc.

4.38%

Illumina, Inc.

4.36%

NeoGenomics, Inc.

3.93%

Corcept Therapeutics, Inc.

3.88%

Repligen Corp.

3.84%

BeOne Medicines Ltd.

3.75%

Genmab A/S

3.72%

Gilead Sciences, Inc.

3.55%

Amgen, Inc.

3.50%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

Trackinsight Global ETF Survey 2026: ETFs' Next Act: From Access to Selection. Access the report

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

First Trust NYSE Arca Biotechnology UCITS ETF

FAQ about FBT

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US